Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II bevacizumab + docetaxel + capecitabine for first-line locally recurrent/metastatic breast cancer
2006-003929-83Phase 2Active
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Jun 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, docetaxel and capecitabine in breast cancer, sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Progression-free survival. Started Jun 2007; status: active.
02
Drugs
bevacizumabdocetaxelcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-003929-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003929-83.